Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
about
Exploiting tumor epigenetics to improve oncolytic virotherapyOncolytic virus therapy: A new era of cancer treatment at dawnOncogenes: The Passport for Viral Oncolysis Through PKR InhibitionClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Going viral: a review of replication-selective oncolytic adenovirusesReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataOncolytic virotherapy for human malignant mesothelioma: recent advancesOncolytic viral therapy for pancreatic cancer: current research and future directionsHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsSerotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus.A phase I trial of single-agent reolysin in patients with relapsed multiple myelomaOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesEnhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportOncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Naturally occurring reoviruses for human cancer therapy.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumorCombination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesAssessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1Trial watch: Oncolytic viruses for cancer therapyReovirus in cancer therapy: an evidence-based reviewOncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Evolution of oncolytic viruses: novel strategies for cancer treatment.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Oncolytic viruses and their application to cancer immunotherapyAntiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Oncolytic virus immunotherapy for melanoma.Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Role of NK cells in immunotherapy and virotherapy of solid tumors.Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy.Targeting Melanoma with Cancer-Killing Viruses.Oncolytic virotherapy for urological cancers.
P2860
Q21131237-0C11719F-2B91-4FA4-8F4D-54FF0A5D0788Q26739714-496D528D-F881-4806-918D-39407998A697Q26739777-4F81C4D1-660F-4BEA-9507-AFB663ECB9D9Q26750568-035E4BC0-93AD-4B5C-9F18-7E177C14539BQ26752807-BAE1F9AD-C815-4D66-B73F-B964CEB52EB4Q26775030-ADFE10FD-5D4B-49D9-AB2C-2AC77AC034A2Q26797520-FA3FA5C6-93D7-42EF-9ADC-6AD65E697780Q26801501-B01B72AB-B9BE-413D-97B4-7EEDFBF47E48Q26826590-C2119300-2AB4-481F-9832-DEDF79B34BEAQ27011439-E8DB7DF2-D4FF-4290-BF72-7B7DAC562471Q28086999-8C814A50-DEAE-4C94-80FC-5CAD53B9582BQ32183285-EB320A12-957D-4732-B37E-91E8D4A57E16Q33418048-E6D35EE5-EF4F-47DD-8B83-E0C616269AB0Q33679505-995AA0EA-44F2-427B-8D91-7D27A201985AQ35051487-4831B177-B7C4-4167-9DFE-4AD7D5C02B3EQ35224368-5D8E02C9-A87E-418F-B830-0B494BB9D2D1Q35812675-4ED88A8B-C365-4207-B940-B0CC85748B19Q36078485-2B131229-27FC-4E76-A9A9-E2E5F29E0D2AQ36390114-010A3A75-D851-447B-B7D3-DB1CC88198DBQ36582819-CDC1EBBE-9DD0-4D3E-BA17-4A09A573BE08Q36664268-4D831D78-9295-48B3-87C2-30FA8F519495Q36956100-1C878D8B-C7BB-434F-A4FD-C84F0930986BQ37028023-0C109CCD-F60B-498D-9D19-FCB2BA7A8A45Q37031909-B67FD885-0578-474C-8AC9-E8DB71165616Q37347236-4B1B0332-26FE-449B-9541-61B3BFA596B3Q37565521-C697BA1D-42E7-448A-9274-8F86F1642088Q37641495-21F81E05-D266-4D19-A674-E8EE6CEDB329Q38152999-31A974FB-18CD-4CC1-992F-16673DA2BADFQ38159802-42397BB3-D84A-4D8B-ABFE-78C056641690Q38194135-96169014-AAE4-4BBA-8672-96534E83BD7CQ38207011-90429947-4D9D-4B5E-9552-24375946E1FAQ38218674-594FB3DB-5B00-4333-9733-213AC42E01D7Q38237657-33145233-C804-46A1-A3F0-587909406448Q38360781-4E7D2F58-B19E-404E-BC2B-38B6FE87440FQ38380394-8BD93BAD-316D-406A-8FD6-BB7A088294EBQ38548938-7BA968A3-74E4-4B91-A1B3-FA554EFB17BAQ38575116-967840A0-B87F-49B0-871B-40532604BC78Q38673407-6421B2F8-C5FE-4451-8552-19C25902770CQ38676416-3CDF4483-E530-4AE3-99EC-E98C454B339AQ38842126-7EE2C8FD-A0DF-4B20-B953-DD9495CC9D10
P2860
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase II trial of intravenous ...... ents with metastatic melanoma.
@ast
Phase II trial of intravenous ...... ents with metastatic melanoma.
@en
type
label
Phase II trial of intravenous ...... ents with metastatic melanoma.
@ast
Phase II trial of intravenous ...... ents with metastatic melanoma.
@en
prefLabel
Phase II trial of intravenous ...... ents with metastatic melanoma.
@ast
Phase II trial of intravenous ...... ents with metastatic melanoma.
@en
P2093
P2860
P356
P1433
P1476
Phase II trial of intravenous ...... ents with metastatic melanoma.
@en
P2093
Gerald P Linette
Gerard J Nuovo
James Zwiebel
Jean E Lewis
Kandelaria M Rumilla
Kari Kendra
Kevin Harrington
Matt Coffey
Michael A Thompson
Richard G Vile
P2860
P304
P356
10.1038/MT.2012.146
P577
2012-08-07T00:00:00Z